Cancer Therapeutics Market Size Expected to Hit USD 469.38 Bn by 2034

According to Precedence Research, the global cancer therapeutics market size is expected to
hit USD 469.38 billion by 2034 from USD 212.58 billion in 2025 and is growing
at a CAGR of 9.20% between 2025 and 2034.

In terms of revenue, the worldwide cancer therapeutics market was
estimated at USD 194.67 billion in 2024 and is anticipated to reach
approximately USD 429.84 billion in 2033. Rise in prevalence of cancer cases
and cancer research, surge in collaboration between pharmaceutical companies,
and growth in geriatric population are the major factors that augment the
growth of the cancer therapeutics market.

Furthermore, according to the Globocan 2020 fact sheet, 19,292,789
new cancer cases were diagnosed worldwide, with nearly 9,958,133 deaths owing
to cancers all around the world.

Note: This report is
readily available for immediate delivery. We can review it with you in a
meeting to ensure data reliability and quality for decision-making.

Download Sample Pages for a Quick Preview 👉 https://www.precedenceresearch.com/sample/1546

Market Overview and Industry Potential

Targeted Therapies and Tech-Driven Solutions Reshape Cancer Care

The
cancer therapeutics market is expected to see rapid growth owing to an
increased focus on the development of drugs and treatment for several cancer
types, such as prostate cancer, breast cancer, and blood cancers, in
the current period. Moreover, the need for better diagnostics and lifestyle
changes is likely to lead the industry growth in the coming years. Also, technological
advancement can play a major role in the market for the future period.

“The
cancer therapeutics landscape is undergoing a paradigm shift, from traditional
chemotherapies to precision and immunotherapies. This evolution, backed by AI
and real-world evidence, is reshaping how we define cancer care,” said Deepa
Pandey, Principal Consultant at Precedence Research.

Cancer
Therapeutics Market Highlights:

🔹North America accounted
for the major revenue share of 36% in 2024.

🔹Asia Pacific is expected
to grow at a significant CAGR from 2025 to 2034.

🔹By application, the lung
cancer segment held the largest revenue share in 2024.

🔹By top-selling drug, the
Revlimid segment contributed the highest revenue share in 2024.

🔹By end use, the cancer and
radiation therapy centers segment is expanding at a notable CAGR 2025 to 2034.

💡 Dive Into the Full Report 👉 https://www.precedenceresearch.com/cancer-therapeutics-market

Manufacturers
Seize Opportunities in Individualized Therapy Solutions

The
increased need for targeted
therapies, immunotherapies, and personalized medicine is
expected to create significant opportunities for manufacturers in the coming years. With
an emphasis on genetic markers, biomarker testing, and companion diagnostics,
cancer therapeutics is shifting toward individualized treatment plans.

Pharmaceutical companies
are investing heavily in precision oncology, exploring areas such as
antibody-drug conjugates (ADCs) and RNA-based drugs, which are poised to
reshape how cancer is managed in the next decade.

Cost
and Timeline Emerge as Major Hurdles in Cancer Drug Development

The
high cost and long development timings are projected to hamper the market
growth in the coming years, as the procedure such as the clinical trails, safety
tastings, and the regulatory approval can be expensive ad time consuming sometimes
which is likely to create the growth barriers for the small and mid-size market
entrants in the coming years as per the industry observations. Moreover, regulatory
approval reflects some of the challenges for manufacturers in the coming years.

Also Read 👉 Advanced Therapy Medicinal
Products Market Analysis: Leading Companies and Innovations

Cancer
Therapeutics Market Report Coverage

Report Attributes

Key Statistics

Market Size in 2024

USD 194.67 Billion

Market Size in 2025

USD 212.58 Billion

Market Size by 2034

USD 469.38 Billion

Growth Rate (2025-2034)

CAGR of 9.20%

Base Year

2024

Forecast Period

2025 to 2034

Largest Market (2024)

North America (36% share; ≈USD 70.08 billion)

Fastest Growing Market

Asia Pacific (significant growth; fastest CAGR region)

U.S. Market Size in 2024

USD 49.06 Billion

U.S. Market Size by 2034

USD 120.78 Billion

Segments Covered

Top Selling Drug, Application, End User, Region

Therapy Type Coverage

Chemotherapy, Immunotherapy, Targeted, Hormonal, Radiation,
Gene/Cell-based

Regions Covered

North America, Europe, Asia-Pacific, Latin America and Middle
East & Africa

Set up a meeting at your convenience
to get more insights instantly! https://www.precedenceresearch.com/schedule-meeting

How Big is the U.S. Cancer Therapeutics Market?

According
to Precedence Research, The U.S. cancer therapeutics market size was valued at
USD 49.06 billion in 2024 and is projected to rise from USD 53.57 billion in
2025 to USD 120.78 billion by 2034. The market is expanding at a solid CAGR of
9.43% between 2025 to 2034.

Note: This report is
readily available for immediate delivery. We can review it with you in a
meeting to ensure data reliability and quality for decision-making.

Download
the Sample Pages of this Report 👉 https://www.precedenceresearch.com/sample/1546

What Makes North America the Leader in Cancer Therapeutics?

North America held the dominant share of the cancer therapeutics
market in 2024, owing to the modern and advanced healthcare infrastructure in
the region. Moreover, the region has seen heavy modern healthcare spending,
akin to its modern population’s needs.

Also, the region has early
access to innovative cancer treatment due to the heavy and technology-driven
research and development activity and its centres. Moreover, the presence of
the major pharmaceutical companies
is actively driving the industry growth in the region, as per the
recent observation.

You can place an order or
ask any questions, please feel free to contact at sales@precedenceresearch.com

Modern Cancer Centres
Shape the Future of Asia Pacific Healthcare

Asia Pacific is expected to expand notably during the forecast
period, owing to a rapid increase in cancer cases and the ongoing healthcare
infrastructure development. Furthermore, countries such the India, China, and others
are seen in putting investment in the development of modern cancer care centres
in their spaces.

Also, these countries have the presence of major pharmaceutical
companies, and the healthcare professional is expected to lead the industry
growth during the forecast period, as per the future industry expectations.

Cancer Therapeutics Market Segmentation Analysis:

Application Type Analysis:

Why Did the Lung Cancer Segment Dominate the Market in 2024?

The lung cancer segment held the largest share of the cancer
therapeutics market in 2024, owing to its being one of the most common and deadliest cancers worldwide.
It is often diagnosed in later stages, requiring aggressive and continuous
treatment, which increases demand for therapeutics. Smoking, pollution, and
aging populations have led to high lung cancer rates, especially in men.

Targeted
therapies and immunotherapies have been developed to treat different types of
lung cancer, improving survival and increasing treatment adoption. Due to its
high mortality rate and large patient pool, the lung cancer segment has
remained the leading application area in the cancer treatment market.

Also Read
👉 How the Lung Cancer Therapeutics
Market Is Evolving with Targeted Therapies

The
breast cancer segment is expected to grow at a notable rate during the
predicted timeframe, owing to increasing awareness, regular screening
programs, and early diagnosis, especially among women. It is the most common
cancer in women worldwide, and survival rates have improved with targeted
therapies and hormone treatments.

Governments
and NGOs actively promote breast cancer education and screening, leading to
higher detection and treatment rates. As more personalized therapies and
immunotherapies are developed for breast cancer, treatment options are
expanding. Combined with rising incidence, early detection, and better
outcomes, the breast cancer segment will likely see the most rapid growth in
the coming years.

Also Read
👉 Cancer Immunotherapy Market Forecast:
Technology, Trials, and Treatment Advances

Top Selling Drug Analysis:

How Revlimid Segment Maintains Its Dominance in the Current Industry?

The Revlimid segment held
the largest share of the market in 2024, akin to its strong effectiveness
in treating myeloma and several blood cancers in the current period. Moreover, having
properties like succens in survival rate and the slower progression of the
disease, Revlimid has gained immense popularity in recent years.

Moreover, the greater approval rate in global countries can drive
the industry growth in the coming years, as the availability of this is reflected
in their own marketing during the project time, as per the future industry
expectations.

Also Read
👉 How the Blood Cancer Diagnostics
Market Is Revolutionizing Hematologic Testing

End
User Analysis:

Why
Did the Cancer and Radiation Therapy Segment Dominate the Market in 2024?

The
cancer and radiation therapy segment dominated the market with the largest
share in 2024, as they provide specialized and comprehensive care for cancer
patients. These centers have the latest equipment for chemotherapy, radiotherapy, and precision
treatments, making them a preferred choice for patients and doctors. They also
offer multidisciplinary care with oncologists, radiologists, and surgeons
working together.

Many
patients require advanced technologies like linear accelerators and proton therapy, which are typically
available only in dedicated centers. As cancer care becomes more specialized,
these facilities continue to be the top places where patients receive complete
and advanced treatment under one roof.

💡Related Topics You May Find Useful:

➢ Next Generation Cancer
Therapeutics Market: The global next-generation
cancer therapeutics market size was estimated at USD 86.20 billion in 2024 and
is predicted to increase from USD 92.54 billion in 2025 to approximately USD
175.20 billion by 2034, expanding at a CAGR of 7.35% from 2025 to 2034.

➢ Cancer Therapeutics and
Biotherapeutics Market: The global
cancer therapeutics and biotherapeutics market size accounted for USD 194.15
billion in 2024 and is expected to exceed around USD 440.59 billion by 2034,
growing at a CAGR of 8.54% from 2025 to 2034.

➢ Cancer Biopsy Market: The global
cancer biopsy market size accounted for USD 30.77 billion in 2024 and is
predicted to increase from USD 36.55 billion in 2025 to approximately USD
172.29 billion by 2034, expanding at a CAGR of 18.80% from 2025 to 2034.

➢ Colorectal Cancer
Therapeutics Market: The global colorectal
cancer therapeutics market size accounted at USD 12.79 billion in 2024 and is
expected to be worth around USD 19.95 billion by 2034, at a CAGR of 4.55% from
2025 to 2034.

➢ Liquid Biopsy Market: The global
liquid biopsy market size was estimated at USD 6.17 billion in 2024 and is
anticipated to reach around USD 22.69 billion by 2034, expanding at a CAGR of
13.91% from 2025 to 2034.

➢ U.S. Liquid Biopsy Market: The market size
was valued at USD 1.85 billion in 2023 and is expected to be worth around USD
6.62 billion by 2033, growing at a CAGR of 13.55% during the forecast period
from 2024 to 2033.

➢ Pet Cancer Therapeutics
Market: The global pet cancer therapeutics market size was estimated at
USD 448.03 million in 2024 and is predicted to increase from USD 493.01 million
in 2025 to approximately USD 1,150.70 million by 2034, expanding at a CAGR of
9.89% from 2025 to 2034.

➢ Small Cell Lung Cancer
Therapeutics Market: The global small cell lung
cancer therapeutics market size accounted for USD 6.46 billion in 2024 and is
anticipated to reach around USD 20.6 billion by 2034, expanding at a CAGR of
12.30% between 2024 and 2034.

➢ Targeted Therapeutics
Market: The global targeted therapeutics market size was USD 80.14 billion
in 2024, estimated at USD 85.75 billion in 2025 and is anticipated to reach
around USD 155.20 billion by 2034, expanding at a CAGR of 6.83% from 2025 to
2034.

Cancer Therapeutics Market Key Players

🔹F. Hoffmann-La Roche AG

🔹Bristol-Myers Squibb
Company

🔹AbbVie, Inc.

🔹Johnson & Johnson

🔹Celgene Corporation

🔹AstellasPharma, Inc.

🔹Pfizer, Inc.

🔹Novartis AG

🔹Merck KGaA

🔹Eli Lilly and Company

“Need a custom strategy for entering the oncology therapeutics
market or tracking competitor drug pipelines? Talk to our research consultants
today.”

📞 Schedule Your Expert
Consultation Today

What is Going Around the Globe?

🔹In 2024, the FDA provided
authorization for pembrolizumab. This is chemotherapy for adult patients who
are suffering from endometrial carcinoma. Moreover, as per the observation of
the FDA, the adverse effects of pembrolizumab and chemoradiotherapy were
similar, as per the report. (Source- https://www.fda.gov)

🔹Approval: In 2024, an article
published by AstraZeneca says the FDA recently approved chemotherapy of
AstraZeneca’s chemotherapy. Chemotherapy is called Imfinzi plus. Also, this
chemotherapy will be used as a treatment for adult patients who are suffering
from primary advanced endometrial cancer, as per the company’s claim.

Strategic Collaborations & Market Trends

🔹 Pfizer and
Arvinas entered a co-development deal for targeted breast cancer
therapies.
🔹 Bristol Myers
Squibb acquired Mirati Therapeutics, focusing on KRAS inhibitors
for lung and colorectal cancers.
🔹 Increasing
adoption of biosimilars for Herceptin, Avastin, and Rituxan is reshaping
competitive pricing.

🔹 Johnson &
Johnson is doubling down on immuno-oncology via its Legend Biotech
collaboration, while Merck is expanding the Keytruda pipeline into new solid
tumor indications, reinforcing the race for dominance in checkpoint inhibitor
therapies.

Cancer Therapeutics Market Segmentation:

By Application

• Blood Cancer

•Lung Cancer

• Colorectal Cancer

• Prostate Cancer

• Breast Cancer

• Cervical Cancer

• Head and Neck Cancer

• Glioblastoma

• Malignant Meningioma

• Mesothelioma

• Melanoma

• Others

By Top Selling Drugs

• Revlimid

• Avastin

• Herceptin

• Rituxan

• Opdivo

• Gleevec

• Velcade

• Imbruvica

• Ibrance

• Zytiga

• Alimta

• Xtandi

• Tarceva

• Perjeta

• Temodar

• Others

By End User

• Hospitals

• Specialty Clinics

• Cancer and Radiation
Therapy Centers

By Geography

• North America

• Europe

• Asia Pacific

• Latin America

• Middle East & Africa (MEA)

Thanks for reading you can
also get individual chapter-wise sections or region-wise report versions such
as North America, Europe, or Asia Pacific.

📥Get Immediate Access | 🛍️ Buy and Download Instantly
👉 https://www.precedenceresearch.com/checkout/1546

You
can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1
804 441 9344

Stay Ahead with Precedence Research
Subscriptions

Unlock
exclusive access to powerful market intelligence, real-time data, and
forward-looking insights, tailored to your business. From trend tracking to
competitive analysis, our subscription plans keep you informed, agile, and
ahead of the curve.

Browse
Our Subscription Plans@ https://www.precedenceresearch.com/get-a-subscription

About
Us

Precedence
Research is a global market intelligence and consulting powerhouse, dedicated
to unlocking deep strategic insights that drive innovation and transformation.
With a laser focus on the dynamic
world of life sciences,
we specialize in decoding the complexities
of cell and gene therapy, drug development, and oncology markets, helping our clients stay
ahead in some of the most cutting-edge and high-stakes domains in healthcare.
Our expertise spans across the biotech and pharmaceutical ecosystem, serving
innovators, investors, and institutions that are redefining what’s possible in regenerative medicine, cancer care, precision
therapeutics, and beyond.